Literature DB >> 24056966

A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop.

S Fernández1, L Genis1, I Torres-Alemán1.   

Abstract

Loss-of-function mutations in the phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome10) contribute to aberrant cell growth in part through upregulation of the mitogenic IGF-1/PI3K/Akt pathway. In turn, this pathway exerts a homeostatic feedback over PTEN. Using mutagenesis analysis to explore a possible impact of this mutual control on astrocyte growth, we found that truncation of the C-terminal region of PTEN (Δ51) associates with a marked increase in NFκB activity, a transcription factor overactivated in astrocyte tumors. Whereas mutations of PTEN are considered to lead to a loss-of-function, PTENΔ51, a truncation that comprises a region frequently mutated in human gliomas, displayed a neomorphic (gain-of-function) activity that was independent of its phosphatase activity. This gain-of-function of PTENΔ51 includes stimulation of IGF-1 synthesis through protein kinase A activation of the IGF-1 promoter. Increased IGF-1 originates an autocrine loop that activates Akt and NFκB. Constitutive activation of NFκB in PTENΔ51-expressing astrocytes leads to aberrant cell growth; astrocytes expressing this mutant PTEN generate colonies in vitro and tumors in vivo. Mutations converting a tumor suppressor such as PTEN into a tumor promoter through a gain-of-function involving IGF-1 production may further our understanding of the role played by this growth factor in glioma growth and help us define druggable targets for personalized therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24056966     DOI: 10.1038/onc.2013.376

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  PTEN proteoforms in biology and disease.

Authors:  Prerna Malaney; Vladimir N Uversky; Vrushank Davé
Journal:  Cell Mol Life Sci       Date:  2017-03-13       Impact factor: 9.261

2.  Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.

Authors:  Brian F Niemeyer; Janet K Parrish; Nicole S Spoelstra; Teresa Joyal; Jennifer K Richer; Paul Jedlicka
Journal:  PLoS One       Date:  2015-01-20       Impact factor: 3.240

3.  microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.

Authors:  Hirofumi Yoshino; Masaya Yonemori; Kazutaka Miyamoto; Syuichi Tatarano; Satoshi Kofuji; Nijiro Nohata; Masayuki Nakagawa; Hideki Enokida
Journal:  Oncotarget       Date:  2017-03-28

Review 4.  Novel Regulators of the IGF System in Cancer.

Authors:  Caterina Mancarella; Andrea Morrione; Katia Scotlandi
Journal:  Biomolecules       Date:  2021-02-12

5.  A scalable Drosophila assay for clinical interpretation of human PTEN variants in suppression of PI3K/AKT induced cellular proliferation.

Authors:  Payel Ganguly; Landiso Madonsela; Jesse T Chao; Christopher J R Loewen; Timothy P O'Connor; Esther M Verheyen; Douglas W Allan
Journal:  PLoS Genet       Date:  2021-09-07       Impact factor: 5.917

Review 6.  Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future.

Authors:  Zhengyang Zhu; Chaoyou Fang; Houshi Xu; Ling Yuan; Yichao Du; Yunjia Ni; Yuanzhi Xu; Anwen Shao; Anke Zhang; Meiqing Lou
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.